Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) CAO Michael Dube sold 2,641 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total transaction of $44,315.98. Following the transaction, the chief accounting officer directly owned 66,886 shares of the company’s stock, valued at approximately $1,122,347.08. This trade represents a 3.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Intellia Therapeutics Stock Performance
Shares of NASDAQ NTLA opened at $17.43 on Wednesday. The company has a market capitalization of $2.44 billion, a PE ratio of -4.92 and a beta of 1.77. The company’s fifty day moving average price is $14.25 and its 200 day moving average price is $13.19. Intellia Therapeutics, Inc. has a 1 year low of $7.95 and a 1 year high of $28.25.
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. The company had revenue of $15.05 million during the quarter, compared to analysts’ expectations of $13.81 million. During the same quarter in the previous year, the company earned ($1.10) earnings per share. On average, equities analysts expect that Intellia Therapeutics, Inc. will post -3.18 EPS for the current year.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on NTLA
Hedge Funds Weigh In On Intellia Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the company. ARK Investment Management LLC lifted its stake in shares of Intellia Therapeutics by 19.2% in the fourth quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock worth $127,724,000 after buying an additional 2,288,146 shares in the last quarter. Vanguard Group Inc. grew its stake in Intellia Therapeutics by 17.8% during the 4th quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock valued at $116,960,000 after acquiring an additional 1,965,181 shares in the last quarter. State Street Corp raised its holdings in Intellia Therapeutics by 29.1% in the 4th quarter. State Street Corp now owns 6,418,836 shares of the company’s stock valued at $57,705,000 after acquiring an additional 1,447,967 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in Intellia Therapeutics in the 1st quarter valued at about $17,913,000. Finally, Renaissance Technologies LLC lifted its stake in Intellia Therapeutics by 156.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,672,700 shares of the company’s stock worth $15,038,000 after purchasing an additional 1,021,700 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.
About Intellia Therapeutics
Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.
Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.
Featured Articles
- Five stocks we like better than Intellia Therapeutics
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
